Who We Are
Clinical Cell Culture (C3) is a company listed on the Australian Stock Exchange (ASX Code CCE) that was established to commercialise a number of autologous tissue engineered products for autologous cell replacement.
C3 is able to provide culture services from laboratories based in Australia and Europe and is expanding their sales, marketing and clinical support programme throughout the world. This has been achieved by employing expert staff in Australia and Europe who are recruiting specialised distributors globally.
Whilst now a commercial entity with operations in Asia-Pacific and Europe, C3 remains committed to the further development of autologous tissue technologies. Ongoing research will result in a pipeline of innovative products that will be used to optimise patients’ outcomes. The use of collaborations with key research groups such as the McComb Foundation will ensure C3 research remains at the forefront of technology.
C3 is also committed to providing the highest level of continuing medical education and clinical support to enable the appropriate use of C3’s tissue engineered products.
